Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28

Lantheus Holdings, Inc.

Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.
Humphrey brings 30+ years clinical oncology experience from Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.
Provost transitions from CMO to CSO to lead business development and pipeline acceleration; holds medicine degree from Sorbonne University.
CEO Markison says moves will 'enable our team to accelerate innovation' in radiopharmaceutical diagnostics and therapeutics.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jean-Claude Provost

Chief Science Officer

LNTH · Lantheus Holdings, Inc.

Effective: 2024-05-28
Filed: May 15, 2024, 7:59 PM ET

On May 15, 2024, Lantheus Holdings, Inc. (the “Company”) announced that, upon the effectiveness of his appointment as Chief Science Officer of the Company on May 28, 2024, Jean-Claude Provost MD will no longer serve as the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Claude Provost was appointed as Chief Science Officer at Lantheus Holdings, Inc..

Action: appointed
Role: Chief Science Officer

Exact text from the filing

On May 15, 2024, Lantheus Holdings, Inc. (the “Company”) announced that, upon the effectiveness of his appointment as Chief Science Officer of the Company on May 28, 2024, Jean-Claude Provost MD will no longer serve as the Company’s Chief Medical Officer.

View on SEC.gov

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-139440

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.